Oppenheimer analyst Matt Biegler reiterated an Outperform rating and $9.00 price target on Zentalis Pharmaceuticals (NASDAQ: ZNTL).The analyst commented: "Zentalis ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE